SRPT
Sarepta Therapeutics
NASDAQ: SRPT · Cambridge, MA · Healthcare
$20.68-0.74 (-3.45%)Closed
Market Cap$11.40B
Cash$1.13Bmost recent
Runway18 mo$155.0M Q burn
P/E (TTM)—EPS $-2.45
52-Wk Range$11.93 – $63.66
Avg Volume6.3M3-month
Healthstable
Genetic medicine company focused on Duchenne muscular dystrophy and other rare neuromuscular diseases.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$20.68-82.3%
Pipeline
Drug candidates sponsored by Sarepta Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | ELEVIDYS | Duchenne Muscular Dystrophy | Not yet recruiting | 2027-03-31 | 1 | |
| Phase 3 | Casimersen | Duchenne Muscular Dystrophy | Terminated | 2023-07-26past | 1 | |
| Phase 3 | SRP-4045 | Duchenne Muscular Dystrophy | Completed | 2024-11-12past | 2 | |
| Phase 3 | eteplirsen | Duchenne Muscular Dystrophy (DMD)+2 more | Active, not recruiting | 2026-10-31 | 7 | |
| Phase 3 | delandistrogene moxeparvovec | Duchenne Muscular Dystrophy+1 more | Recruiting | 2027-05-31 | 9 | |
| Phase 3 | SRP-9003 | Limb-girdle Muscular Dystrophy+2 more | Active, not recruiting | 2028-08-28 | 3 | |
| Phase 3 | SRP-9005 | Muscular Dystrophies, Limb-Girdle | Withdrawn | 2030-11-30 | 1 | |
| Phase 1 | AVI-4065 Injection | Hepatitis C+1 more | Completed | 2006-10past | 2 | |
| Phase 2 | AVI-5126 | Cardiovascular Disease+1 more | Terminated | 2007-11past | 1 | |
| Phase 1 | AVI-4658 for Injection | Duchenne Muscular Dystrophy | Completed | 2010-06past | 1 | |
| Phase 2 | AVI-4658 (Eteplirsen) | Duchenne Muscular Dystrophy+1 more | Completed | 2016-04-15past | 2 | |
| Phase 1 | Placebo | Duchenne Muscular Dystrophy+1 more | Completed | 2019-03-25past | 2 | |
| Phase 1 | SRP-5051 | Muscular Dystrophy, Duchenne | Completed | 2021-08-25past | 2 | |
| Phase 2 | Vesleteplirsen | Duchenne Muscular Dystrophy | Terminated | 2023-10-30past | 1 | |
| Phase 1 | SRP-9004 | Limb-Girdle Muscular Dystrophy, Type 2D+2 more | Completed | 2025-06-18past | 2 | |
| Phase 2 | RESTEN-MP | Coronary Artery Disease+2 more | Completed | — | 2 | |
| Phase 1 | AVI-4126 Injection (RESTEN-NG®) | Neoplasms | Completed | 2006-06past | 1 | |
| Phase 1 | AVI-4020 Injection | West Nile Virus+1 more | Completed | 2006-12past | 2 | |
| Phase 1 | AVI-7100 | Influenza | Terminated | 2011-08past | 1 | |
| Phase 1 | AVI-6003 | Marburg Hemorrhagic Fever | Completed | 2011-12past | 1 | |
| Phase 1 | AVI-7537 | Ebola Hemorrhagic Fever | Withdrawn | 2013-01past | 1 | |
| Phase 1 | AVI-7288 | Marburg Hemorrhagic Fever | Completed | 2014-01past | 1 | |
| Phase 1 | rAAVrh74.MHCK7.DYSF.DV | Dysferlinopathy | Completed | 2019-07past | 1 | |
| Phase 1 | SRP-6004 | Limb Girdle Muscular Dystrophy | Terminated | 2025-06-13past | 1 | |
| Phase 1 | SRP-1005 | Huntington's Disease | Not yet recruiting | 2027-11-30 | 1 | |
| N/A | Unnamed | Limb-girdle Muscular Dystrophy | Active, not recruiting | 2030-09-05 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Gene therapy · rare disease · 4 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.